Company news
Fresenius SE & Co. KGaA news in 2026
Fresenius SE & Co. KGaA's news releases, calls and decks from 2026, newest first.
Fresenius announces intention to sell approximately 13.4 million shares in Fresenius Medical Care AG, reducing its financial investment to approximately 20 per cent
November 11, 2026
Fresenius Q3/2026
November 4, 2026
Supervisory Board appoints Dr. Marc-Alexander Mahl to the Fresenius Management Board and extends Sara Hennicken’s contract
October 15, 2026
Q3 2026 Aide Memoire available
October 13, 2026
Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion
October 1, 2026
Fresenius Kabi Receives Pharmacy Strategic Programs Excellence Award From Vizient®
September 30, 2026
Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform
September 29, 2026
Fresenius expands European production capacity to enhance healthcare supply chain resilience
September 25, 2026
mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
September 18, 2026
Fresenius SE & Co. KGaA: Sara Hennicken, buy
September 10, 2026
Fresenius reorganizes its hospital services business
September 9, 2026
08.09.2026 - Fresenius SE & Co. KGaA: Michael Sen, buy (directors dealings?id=f4bde434 a9a0 477d be62 9746afea402b)
September 8, 2026
Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.
September 3, 2026
Fresenius Medical Care AG: Release of a capital market information
August 31, 2026
Fresenius raises approximately €300 million through sale of 7.8 million Fresenius Medical Care shares
August 20, 2026
Fitch Ratings upgrades outlook for Fresenius SE from stable to positive
August 10, 2026
Fresenius transitions to registered shares – automatic conversion for shareholders
August 6, 2026
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
August 4, 2026
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
August 3, 2026
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
August 3, 2026
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
July 31, 2026
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
July 23, 2026
Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy
July 20, 2026
Q2 2026 Aide Memoire available
July 15, 2026
Fresenius successfully issues €1 billion in bonds
July 1, 2026
Fresenius SE & Co. KGaA: Michael Sen, buy
June 1, 2026
2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
May 22, 2026
Fresenius invests in Avelios Medical and further expands its strategic partnership with SAP
May 6, 2026
CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)
April 9, 2026
AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 22.05.2026 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
April 8, 2026
Dialysis Equipment Market Expands, Led by North America, Europe & Asia with Fresenius, Baxter Innovation
March 27, 2026
Fresenius SE & Co. KGaA: Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026
February 25, 2026
Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
January 14, 2026
Calls in 2026
Decks in 2026
- Q3 2026 Earnings Presentation
Earnings · 60 slides · Nov 4, 2026
- Q3 2026 Earnings Presentation
Earnings · 60 slides · Nov 4, 2026
- Investor Presentation (November 2026)
Investor deck · 50 slides · November 2026
- Q2 2026 Earnings Presentation
Earnings · 56 slides · Aug 5, 2026
- Debt Investor Presentation (August 2026)
Debt investors · 36 slides · August 2026
- Investor Presentation (August 2026)
Investor deck · 57 slides · August 2026
- Q1 2026 Earnings Presentation
Earnings · 47 slides · May 7, 2026
- Investor Presentation (2026)
Investor deck · 50 slides · 2026